D Orazio & Associates Inc. Purchases 362 Shares of Novo Nordisk A/S (NYSE:NVO)

D Orazio & Associates Inc. lifted its stake in Novo Nordisk A/S (NYSE:NVO) by 4.4% during the 1st quarter, Holdings Channel reports. The institutional investor owned 8,655 shares of the company’s stock after purchasing an additional 362 shares during the quarter. D Orazio & Associates Inc.’s holdings in Novo Nordisk A/S were worth $1,111,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. First PREMIER Bank bought a new stake in Novo Nordisk A/S during the 1st quarter valued at approximately $25,000. CNB Bank purchased a new position in shares of Novo Nordisk A/S in the 4th quarter worth approximately $26,000. Dixon Mitchell Investment Counsel Inc. purchased a new position in shares of Novo Nordisk A/S in the 1st quarter worth approximately $26,000. Frank Rimerman Advisors LLC purchased a new position in shares of Novo Nordisk A/S in the 4th quarter worth approximately $30,000. Finally, Kathleen S. Wright Associates Inc. purchased a new position in shares of Novo Nordisk A/S in the 4th quarter worth approximately $31,000. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on NVO shares. Argus lifted their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, June 10th. The Goldman Sachs Group began coverage on Novo Nordisk A/S in a report on Thursday, May 30th. They set a “buy” rating and a $156.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Monday, July 1st. Finally, BMO Capital Markets restated an “outperform” rating and set a $163.00 price objective on shares of Novo Nordisk A/S in a report on Tuesday, June 25th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $145.67.

Novo Nordisk A/S Trading Down 4.0 %

NVO traded down $5.43 during trading hours on Thursday, reaching $129.99. 9,755,919 shares of the company’s stock traded hands, compared to its average volume of 4,460,832. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. The firm has a 50-day moving average price of $138.84 and a 200 day moving average price of $127.16. The firm has a market capitalization of $583.33 billion, a PE ratio of 44.20, a PEG ratio of 1.41 and a beta of 0.41. Novo Nordisk A/S has a 52-week low of $77.96 and a 52-week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.06. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. The company had revenue of $9.52 billion for the quarter, compared to analyst estimates of $9.23 billion. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.4 EPS for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.